ArticlePloS one2026
A network-centric approach reveals novel pathways impacted by Prader-Willi Syndrome.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prader-Willi Syndrome (PWS), a rare multi-system disorder characterized by insatiable appetite, growth abnormalities, and cognitive delay, results from genetic defects in a paternally expressed region of chromosome 15, q11.2-q13. This region contains several protein-coding genes and several genes encoding small nucleolar RNA (snoRNAs), including the SNORD116 gene cluster, but their exact role in PWS remains unclear. Since snoRNAs have wide-ranging effects on protein expression and proteins interact in a complex network, the genetic aberrations causing PWS are likely to cause far-reaching indirect effects on protein expression and activity. Here, we mapped PWS gene expression data onto a human protein-protein interaction (PPI) network and used graph learning techniques to 1) identify the most impacted proteins and 2) suggest novel disease mechanisms. We adapted GeneEMBED, a network-based method originally developed to model genetic variants associated with Alzheimer's Disease. Specifically, we integrated PWS or control expression data with the PPI network, calculated node embeddings, and identified proteins with large differences between PWS and control embeddings. These candidate proteins were subjected to functional enrichment analysis to discover altered biological processes in PWS. Candidate proteins were highly enriched for glycosylated proteins. Analysis of candidate glycosylation enzymes suggested abnormalities in mucin-type O-glycosylation, fucosylation, and glycosaminoglycan synthesis. Defects in these glycosylation pathways have been linked to several PWS phenotypes, including obesity, cognitive delay, and production of secondary sex hormones. Homeobox proteins, master regulators of transcription during development, were also overrepresented among the candidate proteins. In particular, we identified homeobox proteins that drive development of GABAergic and dopaminergic neurons. These neuronal pathways regulate appetite and other behaviors that are abnormal in individuals with PWS. Our results were highly reproducible across PWS model systems. This work offers new avenues for further research in PWS and provides a promising approach that can be applied to other complex diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.